Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Core Viewpoint - Orchestra BioMed Holdings, Inc. has appointed Christopher Cleary as an independent member of its Board of Directors, effective January 30, 2025, bringing over 30 years of experience in corporate development and strategic investments in the medical technology industry [1][2][4] Group 1: Board Appointment - Christopher Cleary's extensive experience includes facilitating over 35 acquisitions and orchestrating a $6 billion sale during his tenure at Medtronic [2][4] - Cleary's role is expected to provide invaluable guidance to enhance the execution of Orchestra BioMed's partnership-enabled business model [2][5] - Eric A. Rose, M.D. will transition to Board Member Emeritus and Strategic Advisor after seven years of service, continuing to support the company's initiatives [3][4] Group 2: Business Model and Collaborations - Orchestra BioMed focuses on risk-reward sharing partnerships with leading medical device companies to drive the commercialization of its products [4][5] - The company's lead product candidate is AVIM therapy for hypertension, which is a significant global health risk [5][7] - Orchestra BioMed has strategic collaborations with Medtronic for AVIM therapy and with Terumo for the Virtue Sirolimus AngioInfusion™ Balloon [5][7] Group 3: AVIM Therapy Details - AVIM therapy is designed to lower blood pressure and has shown promising results in pilot studies, with reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure and 12.3 mmHg in office systolic blood pressure at six months [7] - The BACKBEAT global pivotal study will further evaluate the safety and efficacy of AVIM therapy in patients indicated for dual-chamber cardiac pacemakers [7]